Skip to main content
Fig. 2 | Molecular Brain

Fig. 2

From: Aβ42 treatment of the brain side reduced the level of flotillin from endothelial cells on the blood side via FGF-2 signaling in a blood–brain barrier model

Fig. 2

Aβ42 treatment decreased the flotillin secretion level in the blood-side CM, but did not alter the cellular flotillin level. A The level of flotillin secretion in the blood side increased in a time-dependent manner. The levels of flotillin-1 and -2 in the CM were analyzed by western blotting. B The levels of flotillin-1 and -2 secretion in the blood side were decreased by Aβ treatment, as determined using a fluorogenic substrate. Statistical significance was calculated using one-way ANOVA and the Tukey test (*p < 0.05). Data are shown as the mean ± standard deviation (SD; n = 3). C Cellular flotillin levels were determined by western blotting and densitometry. D Quantification of the protein levels of flotillin-1 and -2 normalized to α-tubulin, and expressed as values relative to the control. Statistical significance was calculated using one-way ANOVA and the Tukey test (*p < 0.05, **p < 0.01). Data are shown as the mean ± SD (n = 3)

Back to article page

Molecular Brain

ISSN: 1756-6606